This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Acute HIV infection syndrome급성 인체면역결핍바이러스감염증후군

Contents and key points
ItemDetails
A. Classification codesICD-10: B23.0 (Acute HIV infection syndrome) | Special Copayment Reduction: V103 (severe intractable disease, 5 years)
B. SynonymsAcute HIV infection; Acute retroviral syndrome (ARS); Primary HIV infection; Acute HIV seroconversion illness; HIV seroconversion syndrome; Acute HIV-1 infection
C. Adult onsetPossibility of presenting in adulthood Very high — acute HIV infection syndrome is an acute viral infection syndrome that occurs within 2-4 weeks after first exposure to HIV and appears mainly in sexually active adults (15-45 years). During this period HIV transmissibility is highest and the HIV antibody test may be negative, so caution is needed in diagnosis.
1. HistoryFirst described in 1985 (Cooper et al., Lancet). Mononucleosis-like syndrome occurring 2-4 weeks after infection. Recognition of high transmissibility in the window period. Since the 1990s, studies of early ART initiation in the acute phase have been active.
2. CausesMucosal or parenteral infection with HIV-1 (mainly CCR5 R5-tropic strains). Sexual contact, blood exposure, vertical transmission. After infection, a rapid decrease in CD4+ T cells and an explosive rise in HIV RNA (peak 10⁷-10⁸ copies/mL). Induces strong innate and adaptive immune responses.
3. GeneticsNot a hereditary disease. CCR5-Δ32 homozygotes resist R5 HIV infection. HLA-B*57:01, B*27:05: enhance HIV-specific CD8+ T-cell responses and favor control of viral load in the acute phase. HLA-B*35: poor control in the acute phase, accelerated disease progression.
4. General epidemiologyClinical symptoms occur in 40-90% of newly HIV-infected persons (the rest are asymptomatic). When symptoms occur, 2-4 weeks is most common. The window period in the acute phase has the highest transmissibility because of the explosive rise in HIV RNA. About 1.5 million new HIV infections occur worldwide each year.
5. PathophysiologyHIV mucosal penetration → capture by dendritic cells → infection of CD4+ T cells in local lymph nodes → systemic dissemination → rapid loss of CD4+ CCR5+ memory T cells (especially in the gut mucosa) → cytokine storm (IFN-α, TNF-α, IL-10) → acute clinical syndrome.
6. SymptomsFever (96%), lymphadenopathy (74%), pharyngitis (70%), rash (70%), myalgia/arthralgia (54%), headache, fatigue. Oral ulcers, esophagitis, nausea and diarrhea, meningitis symptoms (25%). Symptoms last 1-4 weeks and then resolve spontaneously.
7. SignsCervical, axillary, and inguinal lymphadenopathy, throat redness and exudate, maculopapular rash (mainly on the trunk and face), oral and anogenital ulcers. Blood tests: sharp drop in CD4, markedly elevated HIV RNA (>10⁶ copies/mL), lymphopenia followed by an increase in atypical lymphocytes. HIV antibody negative (window period).
8. ScreeningA history of risk exposure to HIV must be taken in patients with a mononucleosis-like syndrome. The fourth-generation HIV Ag/Ab combination test (p24 antigen + antibody) shortens the window period. Quantitative HIV RNA PCR allows the earliest diagnosis.
9. DiagnosisClinical symptoms + detection of HIV RNA (>5000 copies/mL) + fourth-generation Ag/Ab test. Because HIV antibody may be negative in the window period, HIV RNA PCR is the confirmatory criterion. If Western blot is negative or indeterminate and HIV RNA is positive, the acute phase is diagnosed.
10. TreatmentImmediate initiation of ART is recommended (START study and current guidelines). Early initiation of ART in the acute phase minimizes formation of the viral reservoir and favors preservation of immunity. Standard first-line ART: INSTI (dolutegravir or bictegravir)-based combination regimen.
11. PrognosisAcute-phase symptoms resolve spontaneously within 1-4 weeks. The higher the peak viral load in the acute phase, the higher the chronic-phase set point and the faster the progression to AIDS. Acute-phase ART can minimize the reservoir and preserve CD4.
12. PreventionSafe sexual practices such as condom use. Pre-exposure prophylaxis (PrEP: tenofovir/emtricitabine). Post-exposure prophylaxis (PEP: ART initiated within 72 hours). Expanded access to HIV testing. Sex education and risk behavior reduction programs.
13. ReferencesIncludes 10 key references

1. History

Acute HIV infection syndrome (or acute retroviral syndrome, ARS) was first described in 1985 by Cooper et al. of Australia in the Lancet. They reported many patients who experienced, within 2-4 weeks of exposure to HIV, a mononucleosis-like syndrome including fever, lymphadenopathy, pharyngitis, and rash, and showed that these symptoms coincided with HIV seroconversion.

In the early period this syndrome was also called "seroconversion illness" or "primary HIV infection." Until the late 1980s, clinicians often missed the diagnosis by mistaking this acute syndrome mainly for mononucleosis, influenza, or other viral infections. This was because HIV RNA testing was not clinically available at the time and HIV antibody tests were negative before seroconversion.

With the clinical introduction of quantitative HIV RNA testing (RT-PCR) in the 1990s, it was confirmed that HIV RNA rises explosively in the acute phase. The peak HIV RNA in the acute phase reaches 10⁷-10⁸ copies/mL, and it was established that this period has the highest HIV transmissibility. The study by Pilcher et al. (2004) estimated that acute HIV infection may account for about 50% of all sexual transmission, highlighting its public health importance.

From the 2000s, it was shown that in acute HIV infection, CD4+ CCR5+ memory T cells in the gut mucosa (especially the colonic lamina propria) are rapidly lost, by more than 80%, within days to weeks of infection. It was proposed that this "early gut immune collapse" is the origin of the persistent bacterial translocation and immune activation in chronic HIV infection (Guadalupe et al., 2003).

Early initiation of ART in acute HIV infection (the concept of Treatment as Prevention) is now established as an important clinical and public health strategy. Based on the results of the START study (2015) and TEMPRANO study (2015), the CDC/DHHS and WHO guidelines recommend immediate ART for all HIV infections including the acute phase.

2. Causes

Acute HIV infection syndrome is the result of the immune response that occurs in the process in which HIV-1 (rarely HIV-2) first invades the human body and disseminates systemically.

Route of infection and initial infecting virus: sexual transmission is the most common route (about 80% of transmission worldwide), occurring through anal intercourse, vaginal intercourse, and rarely oral sex. Parenteral transmission (intravenous drug injection, transfusion of contaminated blood, medical accidents) and vertical transmission (childbirth, breastfeeding) are also causes. In sexual transmission, the HIV that causes the initial infection is mostly a CCR5-tropic (R5-tropic) strain, because CCR5 is expressed on the mucosal cells that are initially infected (activated CD4+ T cells, dendritic cells).

Initial infection process: when HIV crosses the mucosal barrier, it is first captured by mucosal dendritic cells (Langerhans cells, mucosal dendritic cells). Dendritic cells carry HIV to the local lymph nodes, where they transfer it to CD4+ CCR5+ T cells. After HIV is amplified in the local lymph nodes, it disseminates systemically through the bloodstream. Systemic dissemination begins within 3-5 days of infection, and peak viremia is reached within 1-2 weeks.

Immune activation and cytokine storm: in acute HIV infection, the innate immune system is strongly activated at the same time that HIV RNA rises explosively. Type I interferons (IFN-α, IFN-β), TNF-α, IL-6, and IL-10 rise sharply, causing a cytokine storm. These cytokines cause the clinical symptoms of the acute syndrome (fever, myalgia, lymphadenopathy). NK cells and CD8+ T cells are activated and begin to eliminate HIV-infected cells.

Rapid decline in CD4+ T cells: the CD4+ T-cell count decreases sharply in the acute phase, as a result of the combined action of direct cell destruction by HIV, elimination of infected cells by CD8+ T cells, and cytokine-induced apoptosis. In particular, CCR5+ CD4+ memory T cells of the gut mucosa are preferentially lost, and gut immune collapse begins.

3. Genetics

Acute HIV infection itself is not a hereditary disease, but host genetic factors have an important influence on susceptibility to infection, severity of acute symptoms, and subsequent rate of disease progression.

CCR5-Δ32 mutation: the 32 bp deletion mutation (Δ32) of the CCR5 gene abolishes surface expression of the CCR5 protein. Homozygotes (CCR5-Δ32/Δ32) have more than 99% resistance to infection by R5 HIV. Heterozygotes (CCR5-Δ32/+) can be infected with HIV, but after infection the rate of CD4 decline is slower and progression to AIDS is delayed. This mutation occurs in people of Northern European descent at a frequency of about 1% (homozygotes) and 14-15% (heterozygotes).

HLA alleles: HLA-B*57:01 and HLA-B*27:05 improve the breadth and quality of HIV-specific CD8+ CTL (cytotoxic T lymphocyte) responses, lowering the viral load in the acute phase and delaying disease progression. HLA-B*57:01 carriers have a lower set-point viral load in the acute phase and more of them are long-term non-progressors. HLA-B*35:01 and B*35:03, conversely, are associated with poor viral suppression in the acute phase and rapid progression to AIDS.

HLA-C and KIR genes: alleles that induce high expression of HLA-C improve the ability of NK cells to eliminate HIV-infected cells and favor suppression of viral load. The KIR (killer immunoglobulin-like receptor) gene combination (KIR3DS1+HLA-Bw4-80I) is associated with delayed progression of HIV infection.

Innate immune restriction factors: species-specific polymorphisms of TRIM5α affect the ability to inhibit HIV reverse transcription. APOBEC3G/3F hypermutate viral cDNA during HIV replication, lowering infectivity, and the activity level of this protein is determined by host gene polymorphisms. Tetherin (BST-2) polymorphisms also affect HIV release.

4. General epidemiology

The epidemiology of acute HIV infection syndrome is directly tied to the occurrence of new HIV infections and is central to diagnosis and early intervention in public health.

Symptom incidence: clinical symptoms of the acute syndrome appear in 40-90% of newly HIV-infected people. The remaining 10-60% pass through early infection asymptomatically. When symptoms are present, they are rarely recognized as HIV-specific and diagnosed, and are mostly mistaken for influenza, mononucleosis, or the "common cold."

Timing of transmission and public health: because HIV RNA is extremely high in acute HIV infection (10⁶-10⁸ copies/mL), there is a study (Cohen et al., 2011) showing that the probability of transmission per sexual act is 26- to 55-fold higher than in the chronic phase. In a study by Quinn et al. (2000), the transmission risk from partners with serum HIV RNA >50,000 copies/mL was confirmed to be markedly higher. Some mathematical models suggest that acute HIV infection may account for 26-56% of heterosexual transmission.

Age of onset and risk groups: acute HIV infection occurs most frequently in sexually active adults (15-45 years). Men who have sex with men (MSM) account for a substantial proportion of new HIV infections worldwide. Intravenous drug users, sex workers, and residents of tuberculosis-endemic areas are also high-risk groups.

Epidemiology in Korea: according to Korea Disease Control and Prevention Agency (KDCA) reports, the number of new HIV infections in Korea is about 1,000-1,200 per year. Most new infections (about 90%) are by sexual transmission, and MSM are the largest risk group. The proportion diagnosed at the acute HIV infection stage is increasing, but a considerable number are still first diagnosed at the chronic infection stage.

5. Pathophysiology

The pathophysiology of acute HIV infection syndrome is understood in the sequence from mucosal penetration of HIV through systemic dissemination and immune activation to establishment of the set point.

Stage 1: mucosal penetration (days 0-3): in sexual transmission, HIV enters the submucosal tissue through microscopic damage to the anorectal or vaginal mucosa. Dendritic cells at the mucosal surface (especially mature dendritic cells and macrophages expressing CCR5) capture HIV. HIV directly infects mucosal CD4+ CCR5+ T cells and at the same time is transferred with high efficiency to T cells through the virological synapse formed with dendritic cells.

Stage 2: amplification in local lymph nodes (days 3-7): HIV moves to local (inguinal, mesenteric) lymph nodes and replicates explosively in CD4+ T cells. At this stage HIV RNA begins to be detected in serum for the first time. The virus that causes the initial infection is mainly a single clone (transmitted founder virus), a variant with characteristics suited to crossing the mucosa among a diverse viral population.

Stage 3: systemic dissemination and viral peak (days 7-21): HIV amplified in the lymph nodes disseminates systemically through the bloodstream. CCR5+ CD4+ memory T cells of the gut mucosa (especially the colon) are massively infected and lost. This "gut immune collapse" causes decreased integrity of the intestinal epithelium and bacterial translocation and becomes the origin of chronic immune activation. Serum HIV RNA reaches its peak (10⁷-10⁸ copies/mL), and the CD4+ T-cell count falls sharply (it can transiently drop below 200/μL).

Stage 4: immune response and establishment of the set point (days 21-120): as the HIV-specific CD8+ T-cell response strengthens, the viral load begins to fall from its peak. HIV-specific antibodies appear and seroconversion takes place. The CD4+ T-cell count recovers to some extent but does not return to normal levels. Within 3-6 months each individual's "viral load set point" is established, and this level becomes an important predictor determining the future rate of progression to AIDS.

6. Symptoms

The clinical symptoms of acute HIV infection syndrome are similar to mononucleosis (EBV infection) or influenza and begin 2-4 weeks (range: 1-6 weeks) after HIV exposure.

Frequency of typical symptoms (based on Kahn & Walker 1998): fever 96%, lymphadenopathy 74%, pharyngitis 70%, rash 70%, myalgia 54%, headache 32%, diarrhea 32%, nausea/vomiting 27%, hepatosplenomegaly 14%, weight loss 13%, thrush (oral candidiasis) 12%, neurological symptoms 12%.

Rash: the typical acute HIV rash is an erythematous maculopapular rash 5-10 mm in diameter, distributed mainly on the trunk (chest, abdomen, back), face, and upper limbs. The rash is generally not pruritic and resolves spontaneously within several days to 2 weeks. A bullous rash is rare. Involvement of the palms and soles is a point of differentiation from secondary syphilis (palm and sole involvement is rare in the HIV rash).

Oral and genital ulcers: painful ulcers occur on the oral or genital/anal mucosa in about 10-20%. The ulcers are often well demarcated and occur without surrounding inflammation. This is not an uncommon finding in acute HIV infection and must be differentiated from syphilis or herpes.

Neurological symptoms: meningitis symptoms with headache and photophobia occur in about 24%. CSF examination shows aseptic meningitis (lymphocytic pleocytosis). Rarely, peripheral neuropathy, facial nerve palsy, and Guillain-Barré syndrome occur.

Duration of symptoms and prognostic significance: symptoms generally resolve spontaneously within 1-4 weeks. The longer symptoms last (especially 14 days or more), the higher the acute-phase viral load set point tends to be and the faster the progression to AIDS.

7. Signs

Physical examination findings: high fever (38-40℃), cervical, axillary, and inguinal lymphadenopathy (mostly non-tender, 1-2 cm in diameter). Pharyngeal redness and tonsillar exudate (about 50%). Hepatosplenomegaly (about 14%). Maculopapular rash (predominantly on the trunk and face). Oral and genital ulcers.

Hematological and immunological findings: serum HIV RNA: explosive increase (10⁶-10⁸ copies/mL). CD4+ T-cell count: sharply decreased (several hundred or transiently below 200/μL). Inverted CD4/CD8 ratio (<0.5). Blood tests: lymphopenia (early) followed by increased atypical lymphocytes (late). Thrombocytopenia (10-20%). Mild elevation of AST/ALT (with liver involvement). HIV p24 antigen: detected at high concentration in the acute phase (confirmed by fourth-generation testing). HIV antibody (IgG): initially negative → seroconversion within 3-8 weeks.

Cerebrospinal fluid findings: when meningitis symptoms are present, CSF examination shows mononuclear pleocytosis (10-50 cells/μL), mildly elevated protein, and normal or slightly decreased glucose. CSF HIV RNA positive. It must be distinguished from the purulent CSF of bacterial meningitis.

Imaging findings: mostly normal, but when meningitis accompanies, mild meningeal contrast enhancement may be seen on brain MRI. Chest X-ray is generally normal, but hilar lymph node enlargement is rarely seen.

8. Screening

The screening test strategy for not missing acute HIV infection syndrome depends on clinical suspicion and the choice of an appropriate test method.

Criteria for clinical suspicion: acute HIV infection is strongly suspected when there is an "acute mononucleosis-like syndrome" of fever, lymphadenopathy, pharyngitis, and rash together with a history of HIV risk exposure (condomless sex, needle sharing, blood exposure, etc.) within the past 6 weeks. Sensitivity to this symptom pattern should be raised in sexually transmitted infection clinics, emergency rooms, adolescent medicine, and internal medicine.

Fourth-generation HIV Ag/Ab combination test: the fourth-generation test (CMIA, ECLIA, etc.), which simultaneously detects HIV p24 antigen and HIV-1/2 antibody, shortens the window period to about 2-3 weeks and detects acute HIV infection much earlier than the third-generation test that detects only HIV antibody. It can be positive before seroconversion (HIV p24 antigen positive, antibody negative). When the fourth-generation test is positive, it is confirmed by an HIV differentiation test (antibody/antigen differentiation assay) and HIV RNA PCR.

Quantitative HIV RNA PCR: the most sensitive method and the one that diagnoses acute HIV infection earliest. Positive from 10-11 days after infection (3-5 days earlier than the fourth-generation test). A viral load >5,000 copies/mL strongly suggests acute HIV infection. However, because false positives are possible (low titer: 500-2000 copies/mL), repeat testing and the clinical situation must be evaluated together.

9. Diagnosis

Confirmation of acute HIV infection syndrome is made by a combination of clinical symptoms, detection of HIV RNA, and confirmation of seroconversion.

Diagnostic algorithm (CDC 2014 recommendation): (1) Perform the fourth-generation HIV-1/2 Ag/Ab combination test. (2) If positive: perform an HIV-1/2 antibody differentiation immunoassay. (3) HIV-1 antibody (+): HIV-1 infection confirmed. (4) HIV-1 antibody (-) or indeterminate, HIV-2 antibody (-): perform HIV RNA PCR. (5) HIV RNA (+): acute HIV-1 infection confirmed. (6) HIV RNA (-): HIV negative (or negative verification needed).

Criteria for confirming acute HIV infection: ① HIV RNA > 5,000 copies/mL, ② positive fourth-generation test or positive HIV p24 antigen, ③ negative or indeterminate HIV antibody Western blot, ④ seroconversion to HIV antibody positive confirmed on repeat testing after 3-6 months. Clinical symptoms and a history of risk exposure support the diagnosis.

Differential diagnosis: infectious mononucleosis (EBV): EBV VCA IgM/IgG, monospot test. Cytomegalovirus (CMV) primary infection: CMV IgM. Secondary syphilis: nontreponemal (RPR/VDRL) and specific syphilis antibody tests. Influenza: influenza A/B rapid antigen test. Streptococcal pharyngitis: throat culture. Toxic shock syndrome, drug reaction, etc.

10. Treatment

Early initiation of ART in acute HIV infection syndrome is strongly recommended in all current major guidelines (DHHS, EACS, WHO).

Rationale for immediate ART initiation: in the START study (2015, NEJM), immediate ART initiation regardless of CD4 reduced the risk of clinical events (AIDS and non-AIDS morbidity and mortality) by 57% compared with deferred treatment. Additional benefits of early ART initiation in the acute phase: (1) minimizing formation of the HIV latent reservoir, increasing the possibility of a functional cure; (2) maintaining the CD4+ T-cell count at a high level; (3) preserving gut mucosal CD4 T cells; (4) reducing systemic immune activation; (5) reducing the risk of HIV transmission ("U=U" — Undetectable = Untransmittable).

First-line ART composition (2024 DHHS guidelines): an integrase strand transfer inhibitor (INSTI)-based three-drug combination regimen is standard. Recommended regimens: (1) bictegravir/tenofovir alafenamide/emtricitabine (BIC/TAF/FTC, Biktarvy®) — one tablet daily, first-line recommendation; (2) dolutegravir/abacavir/lamivudine (DTG/ABC/3TC, Triumeq®) — used after confirming HLA-B*57:01 negative; (3) dolutegravir + tenofovir/emtricitabine (DTG + TDF/FTC or TAF/FTC). In the acute phase, same-day ART initiation upon diagnosis ("rapid start" or "same-day start") is recommended.

Symptomatic treatment: acetaminophen for fever and myalgia (caution with NSAIDs: risk of nephrotoxicity). Analgesics and hydration for sore throat. Additional neurology consultation if there are severe neurological complications (meningitis, peripheral neuropathy). After ART is started, most acute symptoms resolve spontaneously within 1-2 weeks.

Partner tracing and prevention: when acute HIV infection is confirmed, HIV testing and post-exposure prophylaxis (PEP) are recommended for sexual contacts within the last 6 weeks to 3 months. Education on notifying sexual contacts and on safe sex is provided to the patient immediately.

11. Prognosis

The short-term clinical prognosis of acute HIV infection syndrome is favorable (mostly resolving spontaneously within several weeks), but the long-term prognosis is determined by the peak viral load in the acute phase and the set point.

Natural course of acute symptoms: most symptoms of the acute syndrome resolve spontaneously within 1-4 weeks regardless of treatment. After symptoms resolve, the patient enters the clinically asymptomatic chronic HIV infection stage. With ART initiation, symptoms resolve faster and the risk of complications is lower.

Viral load set point and progression to AIDS: the more severe and prolonged the acute-phase symptoms, the higher the set-point viral load and the faster the progression to AIDS tend to be. Set-point viral load <1,000 copies/mL: long-term non-progressor pattern. Set point >100,000 copies/mL: very high risk of progression to AIDS within 5 years. If ART is started in the acute phase, the set point itself can be kept low, improving long-term prognosis.

CD4 recovery and long-term prognosis: in patients who start ART in the acute phase, CD4 is maintained at a higher level and the lifelong CD4 profile is more favorable. However, in some studies, even when acute-phase ART is temporarily interrupted (analytic treatment interruption, ATI), viral rebound occurs, suggesting that the HIV reservoir forms rapidly even in the acute phase.

12. Prevention

Condom use: consistent condom use is the most effective barrier method, reducing sexual transmission of HIV by 85-95%. Education on correct condom use and securing access are central to public health strategy.

Pre-exposure prophylaxis (PrEP): oral tenofovir disoproxil/emtricitabine (TDF/FTC) one tablet daily reduces HIV transmission by more than 99% in MSM and heterosexual high-risk groups (iPrEx, PROUD studies). Tenofovir alafenamide/emtricitabine (TAF/FTC) shows equivalent effect in MSM. Injectable cabotegravir (cabotegravir LA) PrEP, an intramuscular injection once every 2 months, was recently approved and solves the problem of medication adherence.

Post-exposure prophylaxis (PEP): taking ART for 28 days within 72 hours after high-risk HIV exposure (condom breakage, sexual assault, needlestick) can prevent HIV infection. PEP is more effective the sooner it is started after exposure (within 24 hours). Recommended PEP regimen: TDF/FTC + dolutegravir or raltegravir.

Expanding access to HIV testing: regular HIV testing in high-risk groups (every 3-6 months) increases diagnosis in the acute phase. Distribution of self-test kits (HIV rapid self-test) increases access to testing. Rapid diagnostic tests provide results the same day to promote linkage to care.

Treatment as prevention (TasP): if HIV RNA is kept undetectable (U) by ART, HIV is not transmitted to sexual partners (U=U principle, PARTNER study). Therefore early diagnosis of HIV-infected persons and immediate ART initiation is a strategy that achieves individual treatment and public health prevention at the same time.

13. References

  1. Cooper DA, Gold J, Maclean P, et al. Acute AIDS retrovirus infection. Definition of a clinical illness associated with seroconversion. Lancet. 1985;1(8428):537-540. PMID: 2857899
  2. Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. N Engl J Med. 1998;339(1):33-39. PMID: 9647878
  3. Pilcher CD, Tien HC, Eron JJ Jr, et al. Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis. 2004;189(10):1785-1792. PMID: 15122514
  4. Guadalupe M, Reay E, Sankaran S, et al. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol. 2003;77(21):11708-11717. PMID: 14557659
  5. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342(13):921-929. PMID: 10738050
  6. INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795-807. PMID: 26192873
  7. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587-2599. PMID: 21091279
  8. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493-505. PMID: 21767103
  9. Rodger AJ, Cambiano V, Bruun T, et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA. 2016;316(2):171-181. PMID: 27404185
  10. Daar ES, Pilcher CD, Hecht FM. Clinical presentation and diagnosis of primary HIV-1 infection. Curr Opin HIV AIDS. 2008;3(1):10-15. PMID: 19372937